Discover new opportunities

Partner with us

Find out how our precision technology can help hospitals, research labs, and medical companies improve their services.


We seek to provide our tumor amplification and early detection services as companion tests to hospitals.

How we detect cancer

Researchers can amplify and store their samples to get a perpetual supply of living cancer cells for future tests.

How we store living cancers

Let us use your drug to identify patients who are likely to benefit from your clinical trials.

How we help with clinical trials

Amplify and store your samples for future use

Track tumor progression

By storing tumor samples throughout a patient's treatment, we can track cancer's chemosensitivity and genetic changes with BEATtumor™ and CAMid™ respectively.

Clinical trials

Evaluate limitless drugs on the same tumor

Control for genetic and environmental variations between individuals by testing your clinical trial drugs on amplified primary cancer cells from the same tumor. This allows for direct comparisons between drugs for each patient sample, giving you efficient and powerful results.

Identify patient populations for clinical trials

We lower the risk of clinical trial failures by identifying patient populations that may benefit from your drugs. Supply us with your chemotherapy drugs and we will use them in our chemosensitivity test. Patients whose tumor samples respond well against your drugs may be good candidates for clinical trials.

Rescue or repurpose drugs

Finding patients who respond to your drugs may allow us to discover unknown patient populations that may benefit. These patients may benefit from a new clinical trial to rescue or repurpose your drugs.

Early detection companion test

Our tumor amplification process can detect cancer cells from a sample containing as few as 10 cancer cells, making it a perfect early detection companion test for regular screenings such as colonoscopies, endoscopies, and pap smears. This high sensitivity is also used to detect minimum residual disease and cancer recurrence after treatment.

Learn more about early detection strategy.

Interested in partnering?

If you have any questions or would like to discuss a partnership, please fill out the form and we will contact you.

You may also email us at